Search the Newsreel

Biomea Fusion doses first patient in icovamenib-semaglutide study

Biomea Fusion, Inc. (NASDAQ:BMEA) has dosed the first patient in a new arm of its OPAL platform study, evaluating the combination of icovamenib and low-dose semaglutide. This randomized double-blind study aims to assess whether adding icovamenib can enhance weight loss and improve physical function, …

Technical Reactions to VPG Trends in Macro Strategies

This article provides a technical analysis of Vishay Precision Group Inc. (NYSE: VPG) using AI models to generate trading strategies. It highlights divergent sentiment across various time horizons, suggesting choppy market conditions for VPG, and outlines specific position trading, momentum breakout, and risk hedging …

CapsoVision Reports Second Quarter 2026 Financial Results

CapsoVision reported second-quarter 2026 revenue of $3.6 million, a 10% increase year-over-year, driven by a 13% rise in CapsoCam Plus capsule sales. The company launched its AI Highlights™ feature internationally and anticipates FDA clearance for the U.S. market by the end of Q3 2026, …

Mun Siong Engineering Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Entravision Communications (EVC) Stock Sinks As Ad Tech Durability Faces Scrutiny

Entravision Communications' (EVC) stock dropped 21% after its Q2 2026 earnings report, despite consolidated sales reaching US$227.9m and operating income turning positive, primarily driven by its Advertising Technology & Services (ATS) segment. Investors are questioning the sustainability of this ad tech surge, especially as …

National Vision Holdings (EYE) Stock May Be Below Fair Value As Shares Fell 65%

Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value

This article identifies three US stocks—Mission Produce (AVO), Xeris Biopharma Holdings (XERS), and Gold Royalty (GROY)—that are estimated to be trading below their intrinsic value based on future cash flow analysis. Despite recent financial challenges, all three companies are projected to experience significant earnings …

Praxis (PRAX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Marcio De'SouzaChief Financial Officer - Tim KellyPresident of Research and Development - Steve PetrouChief Operating Officer - Megan Sniecinski TAKEAWAYS Cash and …

National Vision Stock Down Despite Q2 Earnings & Revenue Beat

National Vision Holdings, Inc. reported stronger-than-expected Q2 2026 earnings and revenues, with adjusted earnings per share of 25 cents beating estimates by 47.1% and net revenues rising 2.5% year over year. Despite the beat and an expanded operating margin, the company's stock fell 7.9% …

UBS Adjusts Price Target on National Vision to $34 From $36, Keeps Buy Rating

UBS has revised its price target for National Vision Holdings, Inc. (EYE) downwards to $34 from $36, while maintaining a Buy rating on the stock. This adjustment comes after National Vision Holdings, Inc. provided updates to its fiscal 2026 earnings guidance and reported its …

National Vision Holdings, Inc. 2026: Revenue $498.81M, EPS $0.15— 10-Q Summary

National Vision Holdings, Inc. (EYE) reported its Q2 2026 results, with revenue reaching $498.81 million and diluted EPS of $0.15, marking a significant increase in net income. The company's growth was attributed to store expansion, improved product mix, higher exam revenue, and strategic digital …

National Vision (EYE) grows revenue and doubles earnings with margin gains in 2026

National Vision Holdings, Inc. (EYE) reported significant growth in revenue and a near doubling of net income for the first half of 2026, driven by new store openings, adjusted comparable store sales growth, and improved margins. The company's net revenue reached $1,042.7 million, with …

HC Wainwright Has Bullish Outlook for DTIL FY2030 Earnings

Wasion Schedules Board Meeting to Approve 2026 Interim Results

Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com

Biomea Fusion has announced the dosing of the first patient in a new arm of its OPAL platform research study. This study will evaluate icovamenib in combination with low-dose semaglutide against semaglutide alone for individuals who are overweight or obese but do not have …

Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss

Biomea Fusion has dosed the first patient in a new arm of its OPAL study, evaluating icovamenib in combination with low-dose semaglutide for overweight or obese adults without type 2 diabetes. The study, in collaboration with the University of Leicester, aims to assess whether …

PensionBee Group Q2 2026 TU Earnings Call Transcript

Biomea Fusion Announces First Patient Dosed in OPAL Study

Biomea Fusion has announced the dosing of the first patient in a new arm of its OPAL study, evaluating icovamenib in combination with low-dose semaglutide for overweight or obese individuals without type 2 diabetes. The study aims to assess whether adding icovamenib can enhance …

Professional Diversity Network, Inc. SEC Filing (Aug 13, 2026)

This article announces that Professional Diversity Network, Inc. (IPDN) had an SEC filing (Form EFFECT) on August 13, 2026, which was accepted by the SEC EDGAR system at 6:32 AM on the same day. The filing pertains to a Notice of Effectiveness for an …

Mizuho Financial Group (FVN) reports 11,000-share holding in Future Vision II

Mizuho Financial Group, Inc. has reported a passive ownership stake of 11,000 common shares, representing 0.1% of the class, in Future Vision II Acquisition Corp. The shares are directly held by Mizuho Securities USA LLC, with Mizuho Financial Group and its other entities being …

Allison Transmission Holdings, Inc. Stock 12‑Month Price Target Raised to $144.14, Implies 17% Upside

The average 12-month price target for Allison Transmission Holdings, Inc. stock has increased to $144.14 from $138.78, according to 7 analysts, suggesting a 17% potential upside from its August 12 closing price. The consensus rating from 10 analysts remains "Buy," with 5 Buy and …

Dimensional Fund Advisors LP Acquires Shares of 216,140 BitMine Immersion Technologies, Inc. $BMNR

Dimensional Fund Advisors LP has acquired 216,140 shares of BitMine Immersion Technologies (NYSE:BMNR) in the first quarter, totaling approximately $4.28 million. Other institutional investors also adjusted their holdings in BMNR, while analyst ratings remain mixed with a "Moderate Buy" consensus but recent target price …

REG - Dekel Agri-Vision - Holding(s) in Company

Immersion Corporation: Revenue and Earnings Analysts Forecasts Revisions | IMMR | US4525211078

Diffusion Engineers hosts virtual investor meet on Aug 19

Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Biomea Fusion Inc (BMEA), detailing analyst ratings and price targets. Seven analysts have given BMEA a "Buy" rating with a target price of $6.50, representing a significant upside. The report also includes past and projected EPS figures …

Earnings Flash (PBEE.L) PensionBee Group Reports H1 Revenue GBP26.4M

Is Sionna Therapeutics (SION) Undervalued After SION 719 Failed And Development Was Halted?

Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?

National Vision Holdings Delivers 2% Revenue Growth in Q2 2026

National Vision Holdings (NASDAQ: EYE) reported adjusted diluted EPS of $0.25 on $486.4M revenue for Q2 2026, marking a 2.5% year-over-year increase. Despite a modest increase and mixed market reaction, the company achieved $12.4M in net income and 3.4% comparable store sales growth. Management …

National Vision Posts Revenue Increase, Stronger Profitability in Q2

National Vision Holdings, Inc. reported a significant increase in net revenue and stronger profitability for Q2 and year-to-date 2026, driven by new store sales, unearned revenue timing, and adjusted comparable store sales growth. The company highlighted strategic initiatives such as a new unified e-commerce …

National Vision Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EYE) 2026-08-12

National Vision Holdings, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Pivot to Quality of Sale and Unified Commerce Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why …

Immersion (NASDAQ:IMMR) Major Shareholder Sells 200,000 Shares of Stock

Major shareholder Toro 18 Holdings Llc sold 200,000 shares of Immersion (NASDAQ:IMMR) stock for over $1 million, reducing its stake by 12.95%. Despite the sale, Immersion recently reported strong quarterly earnings, beating revenue and EPS estimates. The company also pays a quarterly dividend and …

National Vision Holdings Inc (EYE) (Q2 2026) Earnings Call Highlights: Margin Expansion and ...

National Vision Holdings Inc. (EYE) reported a 2.5% increase in net revenue and a 2.2% rise in adjusted comparable store sales for Q2 2026, alongside a significant 140 basis point expansion in adjusted operating margin to 6.3%. Despite a 4.9% decline in customer traffic, …

SION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

Robbins Geller Rudman & Dowd LLP has initiated an investigation into Sionna Therapeutics, Inc. (NASDAQ: SION) following a significant drop in its stock price. The investigation stems from the company's announcement on August 10, 2026, that its SION-719 Phase 2a trial failed to meet …

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Here's Why

Praxis Precision Medicines (NASDAQ:PRAX) recently hit a new 52-week high of $382.97, driven by positive analyst sentiment, including maintained "Buy" ratings and high price targets from HC Wainwright and RBC. The company beat quarterly EPS expectations and is anticipated to have significant catalysts in …